Current Surgical Management of Ovarian Cancer

被引：42
作者：
Schorge, John O. [1 ]
Eisenhauer, Eric E. [2 ]
Chi, Dennis S. [3 ]
机构：
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2012年 / 26卷 / 01期
关键词：
Ovarian cancer; Primary debulking surgery; Interval debulking surgery; Secondary debulking surgery; PRIMARY CYTOREDUCTIVE SURGERY; RECURRENT EPITHELIAL OVARIAN; RANDOMIZED PHASE-III; STAGE-I OVARIAN; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; DEBULKING SURGERY; IMPROVES SURVIVAL; PROGRESSION-FREE;
D O I：
10.1016/j.hoc.2011.10.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Surgical management of ovarian cancer requires excellent judgment and mastery of a wide array of procedures. Involvement of a gynecologic oncologist improves outcomes. Staging of apparent stage I disease is important. Minimally invasive techniques provide advantages. Primary debulking surgery provides the best long-term survival of any strategy in advanced ovarian cancer. Aggressive surgical paradigms have the greatest success. Further cytoreductive surgery may be appropriate. Most relapsed patients require management of bowel obstruction at some point. Palliative intervention can enhance quality of life. Surgical correction may extend survival. For end-stage patients with progressive disease, the treating gynecologic oncologist must manage expectations.
引用
收藏
页码：93 / +
页数：18
相关论文
共 78 条
  • [11] Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    Buys, Saundra S.
    Partridge, Edward
    Black, Amanda
    Johnson, Christine C.
    Lamerato, Lois
    Isaacs, Claudine
    Reding, Douglas J.
    Greenlee, Robert T.
    Yokochi, Lance A.
    Kessel, Bruce
    Crawford, E. David
    Church, Timothy R.
    Andriole, Gerald L.
    Weissfeld, Joel L.
    Fouad, Mona N.
    Chia, David
    O'Brien, Barbara
    Ragard, Lawrence R.
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hartge, Patricia
    Pinsky, Paul F.
    Zhu, Claire S.
    Izmirlian, Grant
    Kramer, Barnett S.
    Miller, Anthony B.
    Xu, Jian-Lun
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2295 - 2303
  • [12] Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: An updated series
    Caceres, Aileen
    Zhou, Qin
    Lasonos, Alexia
    Gerdes, Hans
    Chi, Dennis S.
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : 482 - 485
  • [13] A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not?
    Carney, ME
    Lancaster, JM
    Ford, C
    Tsodikov, A
    Wiggins, CL
    [J]. GYNECOLOGIC ONCOLOGY, 2002, 84 (01) : 36 - 42
  • [14] Pattern of lymph node metastases in clinically unilateral stage invasive epithelial ovarian carcinomas
    Cass, I
    Li, AJ
    Runowicz, CD
    Fields, AL
    Goldberg, GL
    Leuchter, RS
    Lagasse, LD
    Karlan, BY
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 80 (01) : 56 - 61
  • [15] Association of lymphadenectomy and survival in stage I ovarian cancer patients
    Chan, John K.
    Munro, Elizabeth G.
    Cheung, Michael K.
    Husain, Amreen
    Teng, Nelson N.
    Berek, Jonathan S.
    Osann, Kathryn
    [J]. OBSTETRICS AND GYNECOLOGY, 2007, 109 (01) : 12 - 19
  • [16] Influence of the gynecologic oncologist on the survival of ovarian cancer patients
    Chan, John K.
    Kapp, Daniel S.
    Shin, Jacob Y.
    Husain, Amreen
    Teng, Nelson N.
    Berek, Jonathan S.
    Osann, Kathryn
    Leiserowitz, Gary S.
    Cress, Rosemary D.
    O'Malley, Cynthia
    [J]. OBSTETRICS AND GYNECOLOGY, 2007, 109 (06) : 1342 - 1350
  • [17] The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
    Chan, John K.
    Tian, Chunqiao
    Fleming, Gini F.
    Monk, Bradley J.
    Herzog, Thomas J.
    Kapp, Daniel S.
    Bell, Jeffrey
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 301 - 306
  • [18] What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi, D. S.
    Eisenhauer, E. L.
    Lang, J.
    Huh, J.
    Haddad, L.
    Abu-Rustum, N. R.
    Sonoda, Y.
    Levine, D. A.
    Hensley, M.
    Barakat, R. R.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 559 - 564
  • [19] Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less
    Chi, Dennis S.
    Ramirez, Pedro T.
    Teitcher, Jerrold B.
    Mironov, Svetlana
    Sarasohn, Debra M.
    Iyer, Revathy B.
    Eisenhauer, Eric L.
    Abu-Rustum, Nadeem R.
    Sonoda, Yukio
    Levine, Douglas A.
    Brown, Carol L.
    Aghajanian, Carol
    Gershenson, David M.
    Hoskins, William J.
    Hricak, Hedvig
    Barakat, Richard R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 4946 - 4951
  • [20] A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer
    Chi, Dennis S.
    Phaeton, Rebecca
    Miner, Thomas J.
    Kardos, Steven V.
    Diaz, John P.
    Leitao, Mario M., Jr.
    Gardner, Ginger
    Huh, Jae
    Tew, William P.
    Konner, Jason A.
    Sonoda, Yukio
    Abu-Rustum, Nadeem R.
    Barakat, Richard R.
    Jaques, David P.
    [J]. ONCOLOGIST, 2009, 14 (08) : 835 - 839
12345678